

P Barton Duell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10018346/p-barton-duell-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

1,148
citations

17
h-index

33
g-index

64
ext. papers

1,822
ext. citations

4
avg, IF

4.63
L-index

#	Paper	IF	Citations
53	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022 , 101161ATV00000000000000133	9.4	9
52	Real-world utilization of bempedoic acid in an academic preventive cardiology practice.. <i>Journal of Clinical Lipidology</i> , 2021 ,	4.9	2
51	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , ATV00000000000000147	9.4	22
50	Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. <i>American Journal of Preventive Cardiology</i> , 2021 , 5, 100144	1.9	2
49	Cerebrotendinous xanthomatosis without neurological involvement. <i>Journal of Internal Medicine</i> , 2021 , 290, 1039-1047	10.8	0
48	Cerebrotendinous xanthomatosis, sitosterolemia, Smith-Lemli-Opitz syndrome and the seminal contributions of Gerald Salen, MD (1935-2020). <i>Journal of Clinical Lipidology</i> , 2021 , 15, 540-544	4.9	0
47	Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 402-422	4.9	3
46	Use of commercial genetic testing to help reclassify LDL receptor variants in clinical practice: A case report. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 447-450	4.9	
45	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2021 , 6, 100183	1.9	2
44	Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. <i>Journal of Pediatrics</i> , 2021 , 229, 70-77	3.6	4
43	Acute Pancreatitis Due to Hyperchylomicronemia. <i>Contemporary Endocrinology</i> , 2021 , 257-275	0.3	
42	Update on cerebrotendinous xanthomatosis. <i>Current Opinion in Lipidology</i> , 2021 , 32, 123-131	4.4	1
41	Evinacumab for treatment of familial hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 739-751	2.5	2
40	Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	1
39	Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78, e157-e174	3.1	7
38	Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1437-1449	15.1	1
37	Metabolic profiling in serum, cerebrospinal fluid, and brain of patients with cerebrotendinous xanthomatosis. <i>Journal of Lipid Research</i> , 2021 , 62, 100078	6.3	2

36	Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients. <i>JACC: Case Reports</i> , 2020 , 2, 396-399	1.2	4
35	Chylomicronemia syndrome: Familial or not?. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 201-206	4.9	13
34	Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. <i>Journal of Clinical Lipidology</i> , 2020 , 14, e1-e13	4.9	4
33	Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort. <i>Journal of the Endocrine Society</i> , 2020 , 4, bvz015	0.4	6
32	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 398-413	4.9	29
31	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 649-659.e6	4.9	24
30	Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol. <i>American Journal of Preventive Cardiology</i> , 2020 , 1, 100012	1.9	3
29	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020 , 5, 1124-1135	16.2	46
28	Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2020: Part III. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 8-9	0.4	0
27	Lifestyle Modification in the Prevention of Atherosclerotic Cardiovascular Disease. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 10-20	0.4	
26	Low Density Lipoprotein Cholesterol Targets in Secondary Prevention of Atherosclerotic Cardiovascular Disease. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 21-34	0.4	
25	Triglycerides and Atherosclerotic Cardiovascular Disease. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 35-41	0.4	3
24	Lipoprotein(a) and ASCVD risk. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 42-46	0.4	
23	High Sensitivity C-Reactive Protein. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 47-49	0.4	1
22	Apolipoprotein B as a Predictor of CVD. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 50-53	0.4	3
21	Non-HDL Cholesterol and Atherosclerotic Cardiovascular Disease. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 54-58	0.4	
20	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. <i>Atherosclerosis</i> , 2019 , 289, 85-93	3.1	35
19	Prevalence of Cerebrotendinous Xanthomatosis Among Patients Diagnosed With Acquired Juvenile-Onset Idiopathic Bilateral Cataracts. <i>JAMA Ophthalmology</i> , 2019 , 137, 1312-1316	3.9	11

18	Management of dyslipidemia in adult solid organ transplant recipients. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 231-245	4.9	19
17	JCL Roundtable: Lipid clinic operations. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 511-521	4.9	4
16	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1780-1788	27.4	155
15	Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2019 , 8, e013225	6	44
14	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2019 , 124, 32-37	15.7	37
13	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, e38-e81	9.4	231
12	Reduced psychological distress in familial chylomicronemia syndrome after patient support group intervention. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 240-242	4.9	5
11	Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1169-1178	4.9	54
10	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017 , 267, 19-26	3.1	36
9	Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities. <i>Circulation Research</i> , 2017 , 121, 499-501	15.7	22
8	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1223-9	4.9	41
7	Modern Management of Familial Hypercholesterolemia. <i>Metabolic Syndrome and Related Disorders</i> , 2016 , 14, 463-467	2.6	5
6	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 240-9		126
5	PCSK9 Association With Lipoprotein(a). <i>Circulation Research</i> , 2016 , 119, 29-35	15.7	77
4	The extent of familial hypercholesterolemia instruction in US schools and colleges of medicine, pharmacy, and osteopathic medicine. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 281-8	4.9	7
3	Short-term folic acid supplementation induces variable and paradoxical changes in plasma homocyst(e)ine concentrations. <i>Lipids</i> , 2001 , 36 Suppl, S27-32	1.6	14
2	Prevention of atherosclerosis with dietary antioxidants: fact or fiction?. <i>Journal of Nutrition</i> , 1996 , 126, 1067S-71S	4.1	20
1	Hypertriglyceridemia 1992 , 2, 321-331		3

